Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations

v3.26.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Income Statement [Abstract]    
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses 3,736,525 4,161,907
Research and Development Expenses 3,471,841 3,441,010
Stock Based Compensation 2,174,524 1,057,271
Franchise Tax Expense 200,050
Series F-1 Warrant Issuance Expenses 539,097
Series G Warrant Issuance Expenses 969,505
Series H Warrant Issuance Expenses 264,417
Loss from Operations (9,847,357) (10,168,790)
Other (Income) Expenses    
Interest and Dividend Income (225,388) (351,809)
Gain on Sales of Marketable Securities (2,176) (976)
Unrealized Gain on Marketable Securities (38,671) (671)
Impairment on Equity Investment 1,500,000
Change in fair value of Derivatives Liabilities (983,000) 388,000
Change in fair value of Contingent Consideration 1,529,000
Change in fair value of Warrant Liabilities 4,410,000
Loss on issuance of Series F-1 Convertible Preferred Stock 3,737,000
Loss on issuance of Series G Convertible Preferred Stock 5,109,000
Casualty Loss/(Gain) (100,000)
Total Other (Income) Expenses 1,779,765 13,190,544
Loss Before Income Taxes (11,627,122) (23,359,334)
Income Taxes
Net Loss (11,627,122) (23,359,334)
Preferred Stock Dividends 3,357,324 3,801,885
Net Loss Attributable to Common Stockholders $ (14,984,446) $ (27,161,219)
Basic net loss per common share $ (8.66) $ (1,080.87)
Diluted net loss per common share $ (8.66) $ (1,080.87)
Weighted average basic common stock outstanding 1,729,946 25,129
Weighted average diluted common stock outstanding 1,729,946 25,129